Identification and Evaluation of a Highly Effective Fusion Inhibitor for Human MetapneumovirusDEFFRASNES, Céline; HAMELIN, Marie-Eve; PRINCE, Gregory A et al.Antimicrobial agents and chemotherapy. 2008, Vol 52, Num 1, pp 279-287, issn 0066-4804, 9 p.Article

Pharmacokinetics, Metabolism, and Excretion of the Antiviral Drug Arbidol in HumansPAN DENG; DAFANG ZHONG; KATE YU et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 4, pp 1743-1755, issn 0066-4804, 13 p.Article

Successful desensitization of enfuvirtide after a first attempt failureMACHADO, Elizabeth S; PASSONI, Luis Fernando C; SIDI, Leon Claude et al.AIDS (London). 2006, Vol 20, Num 16, pp 2130-2131, issn 0269-9370, 2 p.Article

A Rationally Engineered Anti-HIV Peptide Fusion Inhibitor with Greatly Reduced ImmunogenicityBRAUER, Frances; SCHMIDT, Kerstin; ZAHN, Roland C et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 2, pp 679-688, issn 0066-4804, 10 p.Article

A Fusion Inhibitor Prevents Spread of Immunodeficiency Viruses, but Not Activation of Virus-Specific T Cells, by Dendritic CellsFRANK, I; STÖSSEL, H; GETTIE, A et al.Journal of virology. 2008, Vol 82, Num 11, pp 5329-5339, issn 0022-538X, 11 p.Article

A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtideMYERS, Sarah A; SELIM, Angelica A; MCDANIEL, Margaret A et al.Antiviral therapy (London). 2006, Vol 11, Num 7, pp 935-939, issn 1359-6535, 5 p.Article

Design of inhibitors of influenza virus membrane fusion: Synthesis, structure-activity relationship and in vitro antiviral activity of a novel indole seriesBRANCATO, Virginia; PEDUTO, Antonella; TUFANO, Maria Antonietta et al.Antiviral research. 2013, Vol 99, Num 2, pp 125-135, issn 0166-3542, 11 p.Article

Pharmacokinetics of single and multiple oral doses of arbidol in healthy Chinese volunteersYAXIN SUN; XIAOJING HE; FENG QIU et al.International journal of clinical pharmacology and therapeutics. 2013, Vol 51, Num 5, pp 423-432, issn 0946-1965, 10 p.Article

Amino acid derivatives of the (―) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1TAI AN; OUYANG, Wenjie; WEI PAN et al.Antiviral research. 2012, Vol 94, Num 3, pp 276-287, issn 0166-3542, 12 p.Article

Discovery of HIV fusion inhibitors targeting gp41 using a comprehensive α-helix mimetic libraryWHITBY, Landon R; BOYLE, Kristopher E; LIFENG CAI et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 8, pp 2861-2865, issn 0960-894X, 5 p.Article

Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trialGALLIEN, Sébastien; BRAUN, Josephine; ABOULKER, Jean-Pierre et al.Journal of antimicrobial chemotherapy (Print). 2011, Vol 66, Num 9, pp 2099-2106, issn 0305-7453, 8 p.Article

An Overview on Different Classes of Viral Entry and Respiratory Syncitial Virus (RSV) Fusion InhibitorsMURINEDDU, G; MURRUZZU, C; PINNA, G. A et al.Current medicinal chemistry. 2010, Vol 17, Num 11, pp 1067-1091, issn 0929-8673, 25 p.Article

Drugs in Development for InfluenzaBOLTZ, David A; ALDRIDGE, Jerry R; WEBSTER, Robert G et al.Drugs (Basel). 2010, Vol 70, Num 11, pp 1349-1362, issn 0012-6667, 14 p.Article

Inhibition of HIV-1 by Fusion Inhibitors : Sealing the Envelope-the HIV-1 Envelope Glycoproteins as Targets for Therapeutics and VaccinesEGGINK, Dirk; BERKHOUT, Ben; SANDERS, Rogier W et al.Current pharmaceutical design (Print). 2010, Vol 16, Num 33, pp 3716-3728, issn 1381-6128, 13 p.Article

Interaction Between Enfuvirtide, an Injectable Fusion Inhibitor, and Niacin in an HIV-Infected PatientOATES, Elizabeth; DZINTARS, Kathryn.The Annals of pharmacotherapy. 2010, Vol 44, Num 12, pp 2014-2017, issn 1060-0280, 4 p.Article

In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutationsGOUBARD, Armelle; CLAVEL, François; MAMMANO, Fabrizio et al.Antiviral therapy (London). 2009, Vol 14, Num 4, pp 597-602, issn 1359-6535, 6 p.Article

Identification of a Critical Motif for the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Core Structure : Implications for Designing Novel Anti-HIV Fusion InhibitorsYUXIAN HE; JIANWEI CHENG; JINGJING LI et al.Journal of virology. 2008, Vol 82, Num 13, pp 6349-6358, issn 0022-538X, 10 p.Article

Successful prevention of multidrug resistant HIV mother-to-child transmission with enfuvirtide use in late pregnancyMADEDDU, Giordano; CALIA, Giovanna Maria; LICINIA CAMPUS, Maria et al.International journal of STD & AIDS. 2008, Vol 19, Num 9, pp 644-645, issn 0956-4624, 2 p.Article

Postmarketing Use of Enfuvirtide in Veterans : Provider Compliance with Criteria for Use, Overall Efficacy, and TolerabilityBELPERIO, Pamela S; MOLE, Larry A; HALLORAN, James et al.The Annals of pharmacotherapy. 2008, Vol 42, Num 11, pp 1573-1580, issn 1060-0280, 8 p.Article

CCR5 density levels on primary CD4 T cells impact the replication and enfuvirtide susceptibility of R5 HIV-1HEREDIA, Alonso; GILLIAM, Bruce; DEVICO, Anthony et al.AIDS (London). 2007, Vol 21, Num 10, pp 1317-1322, issn 0269-9370, 6 p.Article

Carbohydrate microarrays as tools in HIV glycobiology : New approaches to HIV-1 inhibitor and vaccine designRATNER, Daniel M; SEEBERGER, Peter H.Current pharmaceutical design. 2007, Vol 13, Num 2, pp 173-183, issn 1381-6128, 11 p.Article

Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitroHEREDIA, Alonso; GILLIAM, Bruce; LATINOVIC, Olga et al.Antimicrobial agents and chemotherapy. 2007, Vol 51, Num 7, pp 2489-2496, issn 0066-4804, 8 p.Article

Lopinavir/ritonavir chez le patient infecté par le VIH en situation d'échec virologique prolongé : évolution immunovirologique et tolérance chez 121 patients de la cohorte ANRS CO8 Aproco-Copilote = Lopinavir/ritonavir in HIV-infected patient with long-term virological failure : immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohortBRUNET-FRANCOIS, C; TAIEB, A; RAFFI, F et al.Médecine et maladies infectieuses. 2007, Vol 37, Num 3, pp 172-177, issn 0399-077X, 6 p.Article

Intensification of Antiretroviral Therapy through Addition of Enfuvirtide in Naive HIV-1-Infected Patients with Severe Immunosuppression Does Not Improve Immunological Response: Results of a Randomized Multicenter Trial (ANRS 130 Apollo)JOLY, Veronique; FAGARD, Catherine; CHENE, Geneviève et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 2, pp 758-765, issn 0066-4804, 8 p.Article

Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtideWEIZSAECKER, K; KUROWSKI, M; HOFFMEISTER, B et al.International journal of STD & AIDS. 2011, Vol 22, Num 5, pp 294-295, issn 0956-4624, 2 p.Article